RemeGen Co. Ltd
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease; and Disitamab Vedotin (RC48), an antibody drug conjugate for … Read more
RemeGen Co. Ltd (REGMF) - Net Assets
Latest net assets as of September 2025: $2.32 Billion USD
Based on the latest financial reports, RemeGen Co. Ltd (REGMF) has net assets worth $2.32 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.97 Billion) and total liabilities ($3.66 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.32 Billion |
| % of Total Assets | 38.81% |
| Annual Growth Rate | N/A |
| 5-Year Change | -44.75% |
| 10-Year Change | N/A |
| Growth Volatility | 33.43 |
RemeGen Co. Ltd - Net Assets Trend (2018–2024)
This chart illustrates how RemeGen Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for RemeGen Co. Ltd (2018–2024)
The table below shows the annual net assets of RemeGen Co. Ltd from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.99 Billion | -42.22% |
| 2023-12-31 | $3.44 Billion | -30.98% |
| 2022-12-31 | $4.98 Billion | +44.51% |
| 2021-12-31 | $3.45 Billion | -4.12% |
| 2020-12-31 | $3.59 Billion | +1649.61% |
| 2019-12-31 | $-231.97 Million | +53.44% |
| 2018-12-31 | $-498.18 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to RemeGen Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 374905800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $544.33 Million | 27.41% |
| Other Components | $5.76 Billion | 290.19% |
| Total Equity | $1.99 Billion | 100.00% |
RemeGen Co. Ltd Competitors by Market Cap
The table below lists competitors of RemeGen Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shandong Weida Machinery Co Ltd
SHE:002026
|
$501.94 Million |
|
Daheng New Epoch Technology Inc
SHG:600288
|
$502.29 Million |
|
Dashang Co Ltd
SHG:600694
|
$502.31 Million |
|
Eco World Develop Group
KLSE:8206
|
$502.55 Million |
|
Kaili Catalyst & New Materials Co. Ltd. A
SHG:688269
|
$501.82 Million |
|
Shenzhen Jinjia Color Printing Group Co Ltd
SHE:002191
|
$501.74 Million |
|
YG Entertainment Inc
KQ:122870
|
$501.74 Million |
|
FORUM ENERGY TECH. DL-01
F:1FE1
|
$501.64 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in RemeGen Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,437,269,000 to 1,986,201,000, a change of -1,451,068,000 (-42.2%).
- Net loss of 1,468,362,000 reduced equity.
- Dividend payments of 69,826,300 reduced retained earnings.
- Other comprehensive income decreased equity by 25,966,306.
- Other factors increased equity by 139,849,606.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.47 Billion | -73.93% |
| Dividends Paid | $69.83 Million | -3.52% |
| Other Comprehensive Income | $-25.97 Million | -1.31% |
| Other Changes | $139.85 Million | +7.04% |
| Total Change | $- | -42.22% |
Book Value vs Market Value Analysis
This analysis compares RemeGen Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.41x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-1.04 | $1.50 | x |
| 2019-12-31 | $-0.48 | $1.50 | x |
| 2020-12-31 | $8.81 | $1.50 | x |
| 2021-12-31 | $7.07 | $1.50 | x |
| 2022-12-31 | $9.38 | $1.50 | x |
| 2023-12-31 | $6.37 | $1.50 | x |
| 2024-12-31 | $3.70 | $1.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently RemeGen Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -73.93%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -85.86%
- • Asset Turnover: 0.31x
- • Equity Multiplier: 2.77x
- Recent ROE (-73.93%) is below the historical average (-21.34%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -2384.49% | 0.02x | 0.00x | $-220.13 Million |
| 2019 | 0.00% | -110271.37% | 0.00x | 0.00x | $-407.08 Million |
| 2020 | -19.41% | 0.00% | 0.00x | 1.15x | $-1.06 Billion |
| 2021 | 8.02% | 19.40% | 0.34x | 1.21x | $-68.38 Million |
| 2022 | -20.06% | -130.09% | 0.13x | 1.21x | $-1.50 Billion |
| 2023 | -43.97% | -140.43% | 0.19x | 1.61x | $-1.85 Billion |
| 2024 | -73.93% | -85.86% | 0.31x | 2.77x | $-1.67 Billion |
Industry Comparison
This section compares RemeGen Co. Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| RemeGen Co. Ltd (REGMF) | $2.32 Billion | 0.00% | 1.58x | $501.91 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |